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Summary A recent report has provided strong evidence for a major prostate cancer susceptibility locus (HPC1) on chromosome 1q24-25
(Smith et al, 1996). Most inherited cancer susceptibility genes function as tumour-suppressor genes (TSGs). Allelic loss or imbalance in
tumour tissue is often the hallmark of a TSG. Studies of allelic loss have not previously implicated the chromosomal region 1q24-25 in
prostate cancer. However, analysis of tumour DNA from cases in prostate cancer families has not been reported. In this study, we have
evaluated DNA from tissue obtained from small families [3-5 affected members (n = 17)], sibling pairs (n = 15) and sporadic (n = 40) prostate
tumours using the three markers from Smith et al (1996) that defined the maximum multipoint linkage lod score. Although widely spaced
(12-50 cM), each marker showed evidence of allelic imbalance in only approximately 7.5% of informative tumours. There was no difference
between the familial and sporadic cases. We conclude that the incidence of allelic imbalance at HPC1 is low in both sporadic tumours and
small prostate cancer families. In this group of patients, HPC1 is unlikely to be acting as a TSG in the development of prostate cancer.
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Numerous studies have provided evidence for familial clustering
of prostate cancer indicating that family history is a major risk
factor for this disease (Cannon et al, 1982; Carter et al, 1993;
reviewed in Eeles et al, 1997). This is at least in part due to genetic
rather than environmental factors because the relative risk of the
disease to first-degree relatives rises markedly when closeness
of clustering or number of cases in a cluster increases (Steinberg
et al, 1990).
Recently, a North American and Swedish collaboration reported
evidence for a prostate cancer susceptibility locus on the long arm
of chromosome 1 (lq24-25) (Smith et al, 1996). This group have
defined a region that may be 12-50 cM in genomic length. This
locus has been designated HPCI (hereditary prostate cancer 1).
The mechanism(s) of action of the prostate cancer predisposition
gene(s) is unknown. Until recently, all familial cancers were
thought to be caused by tumour-suppressor genes (TSGs) (one
exception being the RET proto-oncogene in multiple endocrine
neoplasia type 2 (Mulligan et al, 1993). The presence of TSGs is
often indicated by allelic loss or imbalance in tumour tissue. Many
chromosomal regions have been identified as potential sites of
TSGs in prostate cancer. These include 8p, 8q, 13q, lOp, lOq, 17q,
16q, llp, 18q and Y (reviewed in Eeles RA, 1996). The long arm
of chromosome 1 has not previously been implicated in studies of
allelic imbalance. However, none of these studies to date have
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evaluated tumour tissue from cases likely to have been obtained
from familial (hereditary) prostate cancer cases. This study has
specifically evaluated allelic imbalance at the putative HPCI locus
in tumours obtained from both sporadic and familial prostate
cancer cases.
MATERIALS AND METHODS
Tumour specimens
Seventy-three specimens (tumour and normal) were analysed: 41
were from sporadic tumours obtained after transurethral resection
of the prostate (TURP); complete staging and survival data were
available for this group. Thirty-two specimens were available
from tissue collected through the Cancer Research Campaign/
British Prostate Group (CRC/BPG) UK Familial Prostate Cancer
Study (described in Eeles et al, 1997). Fifteen specimens were
from tumours resected from sibling pairs when either one or both
patients were under the age of 65 years at diagnosis. The
remaining 17 specimens were tumours obtained from patients who
had at least three known family members affected in the same
lineage (range ofaffecteds = 3-5). In total, tissue from five 'pairs'
offirst-degree relatives were available for comparison.
Microdissection
Paraffin sections (15 gm) were cut onto double-sided adhesive
tape, fixed to a glass slide and lightly stained with toluidine blue.
Contiguous sections (4 jum) were stained with haematoxylin and
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1430eosin to identify relevant lesions. Under a dissecting microscope, a
fine scalpel blade was used to microdissect tumour and normal
tissue. Only dense tumour areas were selected for dissection and
contamination with normal tissue was estimated to be less than
10% (SLR). All pathology was reviewed and graded by a single
pathologist (MY).
DNA extraction
DNA was extracted using a modification of the method of Lakhani
et al (1995). In brief, dissected fragments were incubated for 3 days
at 37°C in extraction buffer [10 mM Tris HCL (pH 7.5), 1 mM
EDTA, 1% (w/v) sodium dodecyl sulphate] with 500 ,ug ml'
proteinase K. Fresh proteinase K was added on days 2 and 3 at
250 jg ml'. After thermal inactivation of proteinase K (100°C for
10 min), 100 ,ul of phenol/chloroform/isoamyl alcohol (25:24:1
-Gibco) was added to the DNA solution. This solution was shaken
vigorously and spun. The aqueous layer was collected and washed
with 100 .tl ofchloroform/isoamyl alcohol (49:1). DNA was precip-
itated in 0.1 vols 3 M sodium acetate and 3 vols ethanol. DNA was
washed, dried, then dissolved in 20-60 ,ul ultrapure water (BDH).
Primers and PCR
The three dinucleotide microsatellite markers that provided the
maximum multipoint lod scores described by Smith et al (1996)
were used: D1S2883, DlS158 and D1S422; with the postulated
susceptibility locus mapping closest to DlS422. All have esti-
mated heterozygosity frequencies of greater than 0.69 in the
normal population. One of each primer pair was end-labelled with
0.20 mCi of [32p] y-dATP (ICN). The end-labelling reaction was
conducted for 40 min at 37°C in 1 x reaction buffer I (Stratagene)
with 0.33 units T4-PNK enzyme (Stratagene).
Polymerase chain reaction (PCR) was conducted in 25-,ul reac-
tions containing: 4 jtl purified archival DNA (approximately
100 ng), 0.2 mm each dNTP (0.8 mm total; Stratagene), 1 jtl each
primer (final OD 0.1), 0.75 units of Taq polymerase (Amplitaq
Gold - Perkin Elmer), 1 x reaction buffer [Perkin Elmer (PE) -
reaction buffer II], magnesium chloride at 1.5 mM (PE). The DNA
was amplified in a thermal cycler (Hybaid, Omnigene) using a
'touchdown' programme as follows: initial denaturation at 94°C
for 9 min; denaturing for 1 min, annealing at selected temperature
for 30 sec, extension at 72°C for four cycles. The annealing
temperature was reduced by 2°C every four cycles until the final
annealing temperature was reached, then an additional 34 cycles
were conducted and the reaction completed with a final extension
at 72°C for 10 min. The starting and final annealing temperatures
for the primers were as follows: D1S158 and D1S2883 (64°C
down to 54°C), D S422 (59°C down to 49°C).
PCR products were denatured at 95°C for 6 min with 23 gl of
formamide (containing bromophenol blue and xylene CCF -
Sigma), placed on ice for 6 min then loaded into a 6% polyacry-
lamide gel (National Diagnostics 40%; 19:1 bis:acrylamide)
containing urea at 50% w/v. Gels were run at 80 W for approxi-
mately 3 h in 1 x GTB buffer (tris base, taurine, disodium EDTA).
Gels were removed onto Whatman 3 MM paper, dried, then
exposed to autoradiography film (Amersham) (for permanent hard
copy) and phosphor-images were obtained for analysis with
Molecular Dynamics ImageQuant software. This allowed quantifi-
cation of the PCR product by measurement of the peak height of
the radioactive signal.
Figure 1 Allelic imbalance; representative gels. Alleles are indicated by
arrows. A and B are defined as allelic imbalance: (A) complete allelic
imbalance; (B) 72% allelic imbalance. C does not fulfil the criteria to be
included (60% allelic imbalance, see text). D represents microsatellite
instability [additional band in tumour (indicated)]
Allelic loss was defined as a reduction of 70% or more in the
signal intensity of either tumour allele, when compared with the
corresponding alleles from the non-tumour DNA. Allelic loss for a
specimen pair was only reported ifthe same magnitude ofloss was
obtained on repeated experiment. All experiments were repeated
either two or three times.
In four patients, the presence of additional bands in the tumour
sample (microsatellite instability - MI) was found to be persis-
tently present. Two ofthese samples were from the sporadic group,
and two were from the familial group. It is known that this pattern
of allelic instability is often associated with allelic loss or other
genomic rearrangements (Wooster et al, 1994). We have, there-
fore, included these four findings in our overall definition and
report of allelic imbalance (see Figure 1). The reasons for this are
discussed below.
RESULTS
For each marker, allelic imbalance was detected in approximately
7.5% of tumours. Overall, 9 out of the 73 (12%) tumours showed
allelic imbalance at a minimum of one locus; in 5 of 73 (7%) this
was found at more than one marker (Figure 2). For the three
markers, D1S2883, DIS158 and D1S422, the proportion of infor-
mative tumours demonstrating allelic imbalance at these loci was
7.0%, 7.5% and 7.5% respectively. No associations were found in
a multivariate analysis between allelic imbalance at these loci,
with tumour phenotype (Gleason score; range 2-10), patient age
(mean 69, range 51-77 years), metastatic status, survival, or
number of affecteds in the prostate cancer cluster.
Repeated microsatellite instability was found in one or more of
the three loci in four of the tumours analysed. Two of these were
sporadic tumours, one was in a sibling pair and one in a family
with three affected members.
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Figure 2 Allelic imbalance at the HPC1 locus. W, Normal; *, allelic imbalance (>70% loss); ENl, non-informative; i:., if grouped - cases are first-degree
relatives of each other
DISCUSSION
In many other tumour types, allelic imbalance in tumour tissue has
been reported at sites where TSGs have been lost. For instance,
allelic imbalance on chromosome 13ql2-13 (the site of the breast
cancer predisposition gene, BRCA2) occurs in approximately 90%
ofbreast tumours from individuals linked to BRCA2 (Collins et al,
1995). The allelic imbalance rates that we describe at HPCI are
clearly much lower than for other tumour types where TSGs have
been lost. Furthermore, the rates ofallelic imbalance are generally
lower than for other candidate tumour-suppressor regions pre-
viously described in prostate cancer (Eeles, 1996).
Reasons for this may be inherent in the study design: first, many
of the reported studies of allelic loss in prostate cancer have not
rigorously repeated abnormal findings to confirm that they do not
simply represent PCR artefact. This is understandable as DNA
from microdissected material is a limited resource; most studies
have spread this resource to encompass as many closely spaced
markers as possible. Second, ourcriteria fordefining allelic imbal-
ance were stringent. Prostatic tumour frequently has a marked
stromal component which can provide a source for contamination
of tumour with normal DNA. For this reason, many of the pre-
viously reported studies in the literature have accepted lower
percentages of allelic imbalance as being significant. The require-
ment of at least a 70% reduction in tumour allelic pixel intensity
and, that this reduction be shown on at least two if not three
repeated experiments, inevitably reduces the potential to over-
report allelic imbalance. However, despite our strict criteria for
defining allelic imbalance, we feel that these rates are truly repre-
sentative of a low frequency of imbalance at this locus.
Examination of the 13q region using the same criteria showed an
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imbalance rate of 23%. This is a region of known allelic loss in
prostate cancer and reflects a rate similar to other reported studies.
This indicates that our criteria for allele loss were reasonable.
This is the first study to report on allelic imbalance in DNA
obtained from both prostate cancer families and sporadic cases at
the HPCI locus. In neither group were significant rates of imbal-
ance found. However, it should be noted that in the familial tumour
set, most of the tissue analysed was from affected sibling pairs or
families with relatively small numbers of affected members (range
3-5). In the linkage report from Smith et al (1996), the majority of
families had about five affected individuals in the lineage. More
recent linkage studies have suggested that HPCJ may not be impli-
cated in families with less than three cases ofprostate cancer (Eeles
et al, 1998). Furthermore, there may be racial differences (Smith et
al, 1996) and all our families were Caucasian. Therefore, one
should be cautious before concluding from our data that this region
does not harbour an important TSG. Certainly, the suggestion is
that in small families, sibling pairs and sporadic cases collected in
the UK, large deletions are not common in this part of the human
genome in familial prostate tumours.
However, the study may be offurther interest in that microsatel-
lite instability was observed at one or more ofthe three loci in four
of the tumours analysed. We realise that our decision to include
these four tumours in the overall report of allelic imbalance may
not be justified - MI usually reflects a more generalized genomic
instability and often is associated with other disturbances such as
rearrangements and amplifications (Wooster et al, 1994). It
certainly does not imply that TSGs have been lost at that
microsatellite locus. Therefore, ifthese specimens are not included
in our results, the percentage oftumours showing allelic imbalance
becomes even less. However, including this data may indicate that
other genomic disturbances are important at this locus. These find-
ings may, therefore, be consistent with recent reports of chromo-
some Iq-arm gain that have been identified in up to 52% of
sporadic prostate tumours analysed by comparative genomic
hybridization (CGH) (Cher et al, 1996). Taken together, our results
- along with such studies of CGH - may suggest that although
allele loss is infrequent at HPCI in small families and sporadic
prostate cancer cases, other genomic rearrangements in this region
may be important in a proportion of tumours. In conclusion, we
have not found any evidence for a major tumour-suppressor gene
in the HPCI region in UK familial and sporadic prostatic tumours.
ACKNOWLEDGEMENTS
We are grateful to Dr P Devilee, Dr C Cornelisse and Dr A-M
Cleton-Jansen for helpful discussions, and to all of the patients
O Cancer Research Campaign 1998
who agreed to take part in this study. We would also like to thank
the following for their generous support: The Neil MacTaggart
Fund and Prostate Research Campaign, UK. This study is
supported by The Cancer Research Campaign, UK.
REFERENCES
Cannon L, Bishop DT, Skolnick M, Hunt S, Lyon JL and Smart CR (1982) Genetic
epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Sur'
1: 47-69
Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB and Walsh PC
( 1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol
150: 797-802
Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB
and Jensen RH (1996) Genetic alterations in untreated metastases and
androgen-independent prostate cancer detected by comparative genomic
hybridization and allelotyping. Cancer Res 56: 3091-3102
Collins N, McManus R, Wooster R, Mangion J, Seal S, Lakhani SR, Ormiston W,
Daly PA, Ford D and Easton DF (1995) Consistent loss of the wild type allele
in breast cancers from a family linked to the BRCA2 gene on chromosome
13ql2-13. Onicogenie 10: 1673-1675
Eeles RA (1996) The Genetics ofProstate Can1cer: Cancer Biology anld
Medicinie. Waring M and Ponder BAJ (eds), pp. 67-83. Kluwer Academic
Press: London
Eeles RA, Dearnaley DA, Ardem-Jones A, Shearer RJ, Easton DF, Ford D, Edwards
S, Dowe A and 105 collaborators (1997) Familial prostate cancer: the evidence
and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK
Familial Prostate Cancer Study. BrJ Urol 79: 8-14
Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S.
Biggs P, Deamaley D, Ardem-Jones A, Dowe A, Shearer R, McLennan DL,
Norman RL, Ghadirian P, Aprikian A, Ford D, Amos C and King TM, The
CRC/BPG UK Familial Prostate Cancer Study Collaborators, Labrie F, Simard
J, Narod SA, Easton D and Foulkes WD (1998) Linkage analysis of
chromosome Iq markers in 136 prostate cancer families. Ant J Hunt Geniet
62: 653-658
Lakhani SR, Collins C, Stratton MR and Sloane JP ( 1995) Atypical ductal
hyperplasia ofthe breast: clonal proliferation with loss of heterozygosity on
chromosomes 16q and 17p. J Clin Pathol 48: 611-615
Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR,
Mole SE, Moore JK and Papi L (1993) Germ-line mutations of the ret
proto-oncogene in multiple endocrine neoplasia type 2a. Ncature 363:
458-460
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Issacs SD, Brownstein MJ.
Bova GS, Guo H, Bujnovszky P, Nusskem DR, Damber J, Bergh A,
Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE.
Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM and Issacs WB
(1996) Major susceptibility locus for prostate cancer on chromosome
suggested by a genome wide search. Science 274: 1371-1374
Steinberg GD, Carter BS, Beaty TH, Childs B and Walsh PC (1990) Family history
and the risk ofprostate cancer. Prostate 17: 337-347
Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Comelis RS, Cooper CS,
Gusterson BA, Ponder BA, von Deimling A and Wiestler OD (1994) Instability
of short tandem repeats (microsatellites) in human cancers. Naiture Gettet 6:
152-156
British Journal of Cancer (1998) 78(11), 1430-1433